[
    [
        {
            "time": "2021-02-28",
            "original_text": "西部证券维持智飞生物买入评级：2020年业绩符合预期，看好公司“代理+自研”双轮驱动",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "代理+自研",
                    "双轮驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持智飞生物买入评级：2020年业绩符合预期，看好公司“代理+自研”双轮驱动",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-03",
            "original_text": "3日重挫近20%，智飞生物跌出机会了吗？",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重挫",
                    "下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3日重挫近20%，智飞生物跌出机会了吗？",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-05",
            "original_text": "26股获机构买入型评级 智飞生物关注度最高",
            "features": {
                "keywords": [
                    "智飞生物",
                    "买入型评级",
                    "关注度高"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "26股获机构买入型评级 智飞生物关注度最高",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-06",
            "original_text": "智飞生物：业绩符合预期 管线稳步推进商业化价值可期",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "管线",
                    "商业化"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：业绩符合预期 管线稳步推进商业化价值可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-07",
            "original_text": "快讯 | 智飞生物业绩快报发布：疫苗产品销售稳定增长 实现营业收入151.9亿元净利润33亿元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩快报",
                    "疫苗",
                    "营收",
                    "净利润"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "快讯 | 智飞生物业绩快报发布：疫苗产品销售稳定增长 实现营业收入151.9亿元净利润33亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-08",
            "original_text": "西南证券 - 智飞生物:业绩符合预期，代理产品持续放量",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "代理产品",
                    "放量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券 - 智飞生物:业绩符合预期，代理产品持续放量",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-09",
            "original_text": "持续专注疫苗及生物品研发，智飞生物去年营利齐增",
            "features": {
                "keywords": [
                    "智飞生物",
                    "疫苗",
                    "研发",
                    "营利齐增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "持续专注疫苗及生物品研发，智飞生物去年营利齐增",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-10",
            "original_text": "华西证券维持智飞生物买入评级：利润延续高增长，新冠疫苗有望大幅增厚业绩",
            "features": {
                "keywords": [
                    "智飞生物",
                    "买入评级",
                    "利润",
                    "新冠疫苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华西证券维持智飞生物买入评级：利润延续高增长，新冠疫苗有望大幅增厚业绩",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-11",
            "original_text": "国金证券 - 智飞生物：业绩符合预期，重磅产品管线有序推进",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "重磅产品",
                    "管线"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券 - 智飞生物：业绩符合预期，重磅产品管线有序推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-12",
            "original_text": "中泰证券维持智飞生物买入评级：业绩高速增长，新冠疫苗临床Ⅲ期进展顺利",
            "features": {
                "keywords": [
                    "智飞生物",
                    "买入评级",
                    "业绩",
                    "新冠疫苗",
                    "临床Ⅲ期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持智飞生物买入评级：业绩高速增长，新冠疫苗临床Ⅲ期进展顺利",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]